NCT06866509 - To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients | Biotech Hunter

Enrollment

3,000

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

February 28, 2024

Conditions

Dyslipidemia

Interventions

DRUG

Litorvazet Tablet 10/10mg

Ezetimibe 10 mg + Atorvastatin 10 mg

DRUG

Litorvazet Tablet10/20mg

Ezetimibe 10 mg + Atorvastatin 20 mg

DRUG

Litorvazet Tablet 10/40mg

Ezetimibe 10 mg + Atorvastatin 40 mg

Trial Locations (1)

Korea University Anam Hospital, Seoul